Dana-Farber's 2019 Multiple Myeloma Patient Symposium - | Current & Future Treatment
Watch on YouTube 2019 Multiple Myeloma Symposium | Current & Future Treatment Dana-Farber Cancer Institute Jan 23, 2020 Learn more:...
Dec 12, 2019
Nature Video: Decoding cancer immunology: Hunting hidden tumours
Nature Video: Decoding cancer immunology: Hunting hidden tumours
Dec 12, 2019
NCT04150965: Phase 1/2: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Multiple Myeloma Research Consortium MMRC-089: A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3...
Dec 12, 2019
Myeloma Canada: Patient Handbook - High-dose Therapy and Autologous Stem Cell Transplantation
Myeloma Canada: Patient Handbook - High-dose Therapy and Autologous Stem Cell Transplantation https://myelome.ca/documents/HighDoseTherap...
Dec 12, 2019
What is Plasma Cell Leukemia? HealthTree University Myeloma
What is Plasma Cell Leukemia? HealthTree University Myeloma What is Plasma Cell Leukemia? HealthTree University Myeloma Dec 12, 2019...
Dec 12, 2019
HealthTree University: What is a monoclonal protein (M-protein, M-spike) how is it detected?
What is a monoclonal protein (M-protein, M-spike) how is it detected? HealthTree University Myeloma What is a monoclonal protein...
Dec 12, 2019
NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for ASCT in Myeloma (CarMob)
NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (CarMob)...
Dec 12, 2019
NCCN Webinar : Know What Your Doctors Know: Multiple Myeloma - Part 1 to 11 and Q&A
Know What Your Doctors Know: Multiple Myeloma Part 1 - About NCCN and NCCN Foundation Link to more videos below NCCN: Know What Your...
Dec 11, 2019
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2
TRIMM-2 study A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment...
Dec 11, 2019
NCT04035226 - Study of Real-life Current Standards of Care in Patients With RRMM with 3 prior lines
LocoMMotion Relapsed & Refractory Multiple Myeloma NCT04035226: A Study of Real-life Current Standards of Care in Patients With Relapsed...
Dec 11, 2019
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
CELMoD MM-002 CC-92480-MM-002 (NCT03989414) NCT03989414: A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety...
Dec 11, 2019
NCT03940833: Phase 1/2: Adoptive BCMA CAR-NK Cells - RRMM
Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM The purpose of this study is to infuse BCMA CAR-NK 92 cells to...
Dec 10, 2019
NCT038282: Phase 1 - Dose Esc Study Belantamab mafodotin (GSK2857916) in Japanese With Refr MM
NCT038282: Phase 1 - Dose Esc Study Belantamab mafodotin (GSK2857916) in Japanese With Refr MM Belantamab mafodotin (GSK2857916) is a...
Dec 8, 2019
Different stages of Multiple Myeloma - As per originally used Durie-Salmon staging system
Durie-Salmon staging system for multiple myeloma Stage 1 Low Myeloma cell mass: <0.6 × 1012 cells/m2 + all of the following criteria...
Dec 8, 2019
NCT03836014: Phase 3: IFM 2018-Comparing Continuous Versus Fixed Duration Therapy DRd - RRMM Myeloma
IFM 2018-07 CONFIRM NCT03836014: Phase 3: Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and...
Dec 7, 2019
NCT03859427: Phase 3: Once-weekly vs Twice-wkly Carfilzomib + Lenalidomide + Dex RRMM - A.R.R.O.W.2
A.R.R.O.W.2 NCT03859427: Phase 3: A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and...
Dec 7, 2019
NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma
NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma Denosumab for Smoldering Multiple Myeloma This study will assess the...
Dec 7, 2019
Myeloma UK Publication, intended for UK Audience: Infopack for relapsed and/or refractory myeloma
Myeloma UK Publication, intended for UK Audience Infopack for relapsed and/or refractory myeloma https://www.myeloma.org.uk/...
Dec 7, 2019
NCT04184050: Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM
NCT04184050: Phase 1/2: Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217...
Dec 7, 2019